RICHMOND, British Columbia--(BUSINESS WIRE)--Dec. 4, 1996-- HELIX BIOPHARMA
CORP. (TSE/VSE:HBP) Helix BioPharma Corp. has entered into an agreement with
Mr. Timothy J. Fussner to  assist the Company in its Investor Relations
program.  With his  twenty-five years of experience in the securities
markets, both  Canadian and foreign, Mr. Fussner will focus his efforts in
 disseminating corporate information to professional money managers and the
investment dealer community, especially their research and corporate finance
departments and sales managers. 

Mr. Fussner will be compensated with $4,000 per month,  plus reasonable
expenses, and the issue of a 60,000 stock option,  at $2.00 per share. 

Helix BioPharma Corp. is a company which actively  develops, licenses,
markets, and distributes quality bio-medical  and pharmaceutical products,
technologies, and services  domestically and internationally. 

Dated at Richmond, B.C. this 4th Day of December, 1996. ON BEHALF OF THE
BOARD 

Terrance G. Owen, Ph.D., M.B.A., President -0- 

Note to Editors:  The Vancouver Stock Exchange has not reviewed and does not
accept responsibility for the adequacy of the content of the information
contained herein.   

CONTACT:  

Helix Biopharma Corp. 

Jason Van Bergen, 604/270-7468 or 800/563-4363 

604/270-8208 (fax) 

Internet:  http://www.helixbio.com 

e-mail:  invrelations@helixbiopharma.ca 

KEYWORD:  NEW YORK 

INDUSTRY KEYWORD:  PHARMACEUTICAL BIOTECHNOLOGY MEDICINE 

BW0353  DEC 04,1996